ShockWave Medical, Inc. (NASDAQ:SWAV) Shares Sold by Lazard Asset Management LLC

Lazard Asset Management LLC lessened its stake in ShockWave Medical, Inc. (NASDAQ:SWAVGet Rating) by 78.1% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 1,056 shares of the company’s stock after selling 3,756 shares during the period. Lazard Asset Management LLC’s holdings in ShockWave Medical were worth $201,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Lincoln National Corp acquired a new position in ShockWave Medical in the first quarter valued at $211,000. New York State Teachers Retirement System acquired a new stake in shares of ShockWave Medical during the second quarter worth about $7,258,000. Level Four Advisory Services LLC boosted its stake in shares of ShockWave Medical by 21.2% during the first quarter. Level Four Advisory Services LLC now owns 4,426 shares of the company’s stock worth $918,000 after buying an additional 773 shares during the period. Calamos Advisors LLC boosted its stake in shares of ShockWave Medical by 9.6% during the second quarter. Calamos Advisors LLC now owns 25,735 shares of the company’s stock worth $4,919,000 after buying an additional 2,246 shares during the period. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of ShockWave Medical during the second quarter worth about $883,000. Institutional investors and hedge funds own 95.40% of the company’s stock.

Insider Buying and Selling at ShockWave Medical

In other ShockWave Medical news, CEO Douglas Evan Godshall sold 30,000 shares of the stock in a transaction dated Monday, November 14th. The shares were sold at an average price of $240.81, for a total value of $7,224,300.00. Following the completion of the transaction, the chief executive officer now directly owns 82,926 shares of the company’s stock, valued at $19,969,410.06. The sale was disclosed in a filing with the SEC, which is available at this link. In other ShockWave Medical news, Director Frank T. Watkins sold 3,000 shares of the stock in a transaction dated Thursday, November 17th. The shares were sold at an average price of $244.44, for a total value of $733,320.00. Following the completion of the transaction, the director now directly owns 3,796 shares of the company’s stock, valued at $927,894.24. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Douglas Evan Godshall sold 30,000 shares of the stock in a transaction dated Monday, November 14th. The shares were sold at an average price of $240.81, for a total transaction of $7,224,300.00. Following the completion of the transaction, the chief executive officer now directly owns 82,926 shares of the company’s stock, valued at $19,969,410.06. The disclosure for this sale can be found here. Over the last three months, insiders sold 57,350 shares of company stock valued at $14,927,408. Corporate insiders own 3.90% of the company’s stock.

ShockWave Medical Trading Up 0.7 %

NASDAQ SWAV opened at $249.78 on Monday. The stock has a market capitalization of $9.03 billion, a P/E ratio of 107.20 and a beta of 1.03. ShockWave Medical, Inc. has a 52-week low of $113.36 and a 52-week high of $320.54. The firm has a 50-day moving average price of $272.96 and a 200 day moving average price of $233.39. The company has a quick ratio of 6.02, a current ratio of 7.29 and a debt-to-equity ratio of 0.04.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Morgan Stanley increased their target price on shares of ShockWave Medical from $255.00 to $290.00 and gave the stock an “equal weight” rating in a research note on Tuesday, October 11th. Canaccord Genuity Group increased their target price on shares of ShockWave Medical from $232.00 to $256.00 and gave the stock a “buy” rating in a research note on Tuesday, August 9th. Wells Fargo & Company increased their target price on shares of ShockWave Medical from $255.00 to $300.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 8th. Oppenheimer downgraded shares of ShockWave Medical from a “market perform” rating to an “underperform” rating and set a $165.00 target price for the company. in a research note on Tuesday, September 6th. Finally, Piper Sandler increased their price target on shares of ShockWave Medical from $278.00 to $338.00 and gave the stock an “overweight” rating in a report on Monday, August 29th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, ShockWave Medical currently has a consensus rating of “Moderate Buy” and a consensus target price of $263.00.

ShockWave Medical Profile

(Get Rating)

ShockWave Medical, Inc, a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD.

Further Reading

Want to see what other hedge funds are holding SWAV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ShockWave Medical, Inc. (NASDAQ:SWAVGet Rating).

Institutional Ownership by Quarter for ShockWave Medical (NASDAQ:SWAV)

Receive News & Ratings for ShockWave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ShockWave Medical and related companies with MarketBeat.com's FREE daily email newsletter.